Login
Evidence Feed
About
Diagnostics
New
Top genes
FAQ
Contact us
^
Login
Contact us
to learn more about
our Premium Content: News alerts, weekly reports and conference planners
BIOMARKER:
KMT2A rearrangement
i
Other names:
KMT2A, Lysine Methyltransferase 2A, Histone-Lysine N-Methyltransferase 2A, CXXC7, TRX1, Myeloid/Lymphoid Or Mixed-Lineage Leukemia (Trithorax Homolog, Drosophila), Lysine (K)-Specific Methyltransferase 2A, CXXC-Type Zinc Finger Protein 7, Lysine N-Methyltransferase 2A, Zinc Finger Protein HRX, Trithorax-Like Protein, HTRX1, MLL1A, MLL1, MLL, Myeloid/Lymphoid Or Mixed-Lineage Leukemia (Trithorax (Drosophila) Homolog), Myeloid/Lymphoid Or Mixed-Lineage Leukemia Protein 1, Myeloid/Lymphoid Or Mixed
Contact us
to learn more about our Premium Content:
News alerts, weekly reports and conference planners
Entrez ID:
4297
Related biomarkers:
Expression
Mutation
Fusion
Others
‹
KMT2A-AFF1 fusion (1)
KMT2A-AFF1 fusion (1)
›
Related tests:
MLL (KMT2A) Breakapart Fish Probe Kit
MLL (KMT2A) Breakapart Fish Probe Kit
Associations
News
Trials
VERI cancer hierarchy
Reset Filters
KMT2A rearrangement
Acute Lymphocytic Leukemia
KMT2A rearrangement
Acute Lymphocytic Leukemia
CEP-701
Sensitive: B - Late Trials
CEP-701
Sensitive
:
B
CEP-701
Sensitive: B - Late Trials
CEP-701
Sensitive
:
B
KMT2A rearrangement
Acute Myelogenous Leukemia
KMT2A rearrangement
Acute Myelogenous Leukemia
SNDX-5613
Sensitive: B - Late Trials
SNDX-5613
Sensitive
:
B
SNDX-5613
Sensitive: B - Late Trials
SNDX-5613
Sensitive
:
B
KMT2A rearrangement
Acute Lymphocytic Leukemia
KMT2A rearrangement
Acute Lymphocytic Leukemia
SNDX-5613
Sensitive: B - Late Trials
SNDX-5613
Sensitive
:
B
SNDX-5613
Sensitive: B - Late Trials
SNDX-5613
Sensitive
:
B
KMT2A rearrangement
Acute Myelogenous Leukemia
KMT2A rearrangement
Acute Myelogenous Leukemia
DSP-5336
Sensitive: B - Late Trials
DSP-5336
Sensitive
:
B
DSP-5336
Sensitive: B - Late Trials
DSP-5336
Sensitive
:
B
KMT2A rearrangement
Acute Myelogenous Leukemia
KMT2A rearrangement
Acute Myelogenous Leukemia
KO-539
Sensitive: C2 – Inclusion Criteria
KO-539
Sensitive
:
C2
KO-539
Sensitive: C2 – Inclusion Criteria
KO-539
Sensitive
:
C2
KMT2A rearrangement
Acute Myelogenous Leukemia
KMT2A rearrangement
Acute Myelogenous Leukemia
gemtuzumab ozogamicin
Sensitive: C3 – Early Trials
gemtuzumab ozogamicin
Sensitive
:
C3
gemtuzumab ozogamicin
Sensitive: C3 – Early Trials
gemtuzumab ozogamicin
Sensitive
:
C3
KMT2A rearrangement
Childhood B Acute Lymphoblastic Leukemia
KMT2A rearrangement
Childhood B Acute Lymphoblastic Leukemia
blinatumomab
Sensitive: C3 – Early Trials
blinatumomab
Sensitive
:
C3
blinatumomab
Sensitive: C3 – Early Trials
blinatumomab
Sensitive
:
C3
KMT2A rearrangement
Acute Myelogenous Leukemia
KMT2A rearrangement
Acute Myelogenous Leukemia
venetoclax
Sensitive: C3 – Early Trials
venetoclax
Sensitive
:
C3
venetoclax
Sensitive: C3 – Early Trials
venetoclax
Sensitive
:
C3
KMT2A rearrangement
Acute Myelogenous Leukemia
KMT2A rearrangement
Acute Myelogenous Leukemia
venetoclax + sunitinib + I-BET151
Sensitive: C3 – Early Trials
venetoclax + sunitinib + I-BET151
Sensitive
:
C3
venetoclax + sunitinib + I-BET151
Sensitive: C3 – Early Trials
venetoclax + sunitinib + I-BET151
Sensitive
:
C3
KMT2A rearrangement
Acute Myelogenous Leukemia
KMT2A rearrangement
Acute Myelogenous Leukemia
venetoclax + SNDX-5613
Sensitive: C3 – Early Trials
venetoclax + SNDX-5613
Sensitive
:
C3
venetoclax + SNDX-5613
Sensitive: C3 – Early Trials
venetoclax + SNDX-5613
Sensitive
:
C3
KMT2A rearrangement
B Acute Lymphoblastic Leukemia
KMT2A rearrangement
B Acute Lymphoblastic Leukemia
blinatumomab
Sensitive: C3 – Early Trials
blinatumomab
Sensitive
:
C3
blinatumomab
Sensitive: C3 – Early Trials
blinatumomab
Sensitive
:
C3
KMT2A rearrangement
B Acute Lymphoblastic Leukemia
KMT2A rearrangement
B Acute Lymphoblastic Leukemia
bortezomib + vorinostat + dexamethasone + mitoxantrone
Sensitive: C3 – Early Trials
bortezomib + vorinostat + dexamethasone + mitoxantrone
Sensitive
:
C3
bortezomib + vorinostat + dexamethasone + mitoxantrone
Sensitive: C3 – Early Trials
bortezomib + vorinostat + dexamethasone + mitoxantrone
Sensitive
:
C3
KMT2A rearrangement
Acute Lymphocytic Leukemia
KMT2A rearrangement
Acute Lymphocytic Leukemia
azacitidine
Sensitive: C4 – Case Studies
azacitidine
Sensitive
:
C4
azacitidine
Sensitive: C4 – Case Studies
azacitidine
Sensitive
:
C4
KMT2A rearrangement
Childhood B Acute Lymphoblastic Leukemia
KMT2A rearrangement
Childhood B Acute Lymphoblastic Leukemia
DS-1594
Sensitive: D – Preclinical
DS-1594
Sensitive
:
D
DS-1594
Sensitive: D – Preclinical
DS-1594
Sensitive
:
D
KMT2A rearrangement
Acute Lymphocytic Leukemia
KMT2A rearrangement
Acute Lymphocytic Leukemia
FLT3 inhibitor + gilteritinib
Sensitive: D – Preclinical
FLT3 inhibitor + gilteritinib
Sensitive
:
D
FLT3 inhibitor + gilteritinib
Sensitive: D – Preclinical
FLT3 inhibitor + gilteritinib
Sensitive
:
D
KMT2A rearrangement
Acute Lymphocytic Leukemia
KMT2A rearrangement
Acute Lymphocytic Leukemia
Menin-MLL inhibitor
Sensitive: D – Preclinical
Menin-MLL inhibitor
Sensitive
:
D
Menin-MLL inhibitor
Sensitive: D – Preclinical
Menin-MLL inhibitor
Sensitive
:
D
KMT2A rearrangement
B Acute Lymphoblastic Leukemia
KMT2A rearrangement
B Acute Lymphoblastic Leukemia
PRT2527
Sensitive: D – Preclinical
PRT2527
Sensitive
:
D
PRT2527
Sensitive: D – Preclinical
PRT2527
Sensitive
:
D
KMT2A rearrangement
Acute Myelogenous Leukemia
KMT2A rearrangement
Acute Myelogenous Leukemia
SNDX-5613 + ORY-1001
Sensitive: D – Preclinical
SNDX-5613 + ORY-1001
Sensitive
:
D
SNDX-5613 + ORY-1001
Sensitive: D – Preclinical
SNDX-5613 + ORY-1001
Sensitive
:
D
^
^
Full access to predictive biomarker details and heatmap analytics are available with a VERI Account.
Sign up for FREE
Already have an account?
Login
Full access to predictive biomarker details and heatmap analytics are available with a VERI Account.
Sign up for FREE
Already have an account?
Login